The patent expiration timeline for Austedo (deuteratedイツ) is a critical factor for its future market availability and the potential entry of generic alternatives. Understanding these dates is essential for manufacturers, healthcare providers, and patients.
When Does Austedo's Main Patent Expire?
Austedo's primary patent, U.S. Patent No. 9,174,051, which covers the composition of matter for deuteratedイツ, is set to expire in September 2033. This patent is held by Teva Pharmaceuticals [1].
What Other Patents Protect Austedo?
Beyond the composition of matter patent, Austedo is protected by several other patents, including those related to its manufacturing processes and specific formulations. For example, U.S. Patent No. 10,675,560, which relates to processes for producing deuteratedイツ, has a listed expiration date of October 2036 [1]. DrugPatentWatch.com tracks these numerous patents, offering detailed insights into their expiry dates and potential challenges [1].
Could Generic Austedo Enter Before Patent Expiration?
The entry of generic Austedo before the expiration of all relevant patents would likely depend on the outcome of any patent litigation or successful challenges to the validity of Teva's patents. Companies seeking to market generic versions often initiate Paragraph IV certifications, challenging the listed patents [2]. If these challenges are successful, or if Teva's patents are otherwise invalidated or circumvented, it could lead to earlier generic availability.
How Does Austedo Compare to Other Treatments for Tardive Dyskinesia?
Austedo is used to treat tardive dyskinesia and chorea associated with Huntington's disease. It is a deuterated form ofイツ. Other treatments for tardive dyskinesia include older antipsychotic medications and other VMAT2 inhibitors. VMAT2 inhibitors, like Austedo and Ingrezza, work by affecting dopamine levels in the brain. Austedo has shown efficacy in clinical trials for reducing involuntary movements associated with tardive dyskinesia [3].
What is the Mechanism of Action for Austedo?
Austedo is a selective VMAT2 inhibitor. VMAT2 is a protein that transports monoamines, such as dopamine, from the cytoplasm into storage vesicles. By inhibiting VMAT2, Austedo reduces the storage and release of dopamine in the brain. This reduction in dopamine is believed to alleviate the involuntary movements characteristic of tardive dyskinesia [3].
What Are the Risks and Side Effects of Austedo?
Common side effects of Austedo can include somnolence and fatigue, dry mouth, constipation, nausea, vomiting, and headache. More serious potential side effects include depression and suicidal thoughts or behaviors, parkinsonism, and QT interval prolongation. Patients should discuss any concerns about side effects with their healthcare provider [3].
Sources:
[1] DrugPatentWatch.com. "Austedo." https://drugpatentwatch.com/drugs/austedo
[2] U.S. Food and Drug Administration. "Abbreviated New Drug Applications (ANDAs) for Generic Drugs." https://www.fda.gov/drugs/abbreviated-new-drug-applications-andas-generic-drugs/abbreviated-new-drug-applications-andas-generic-drugs
[3] U.S. Food & Drug Administration. "FDA Approved Drug Products." https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=search.process